Ticker Symbol: XRTX
XORTX Therapeutics Inc
$2.88 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
Canada
Currency:
USD
Asset
Type: Common Stock
CIK:0001729214
Company Profile
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX Therapeutics is dedicated to developing medications to improve the quality of life and future health of patients.
Sector: Mining, Quarrying, and Oil and Gas Extraction
Industry: Support Activities for Nonmetallic Minerals (except Fuels) Mining
Standard Industrial Classification Code (SIC code): 2833
Address: Suite 4000, 421 - 7th Avenue SW
Website: www.xortx.com
CEO: Allen Davidoff
Tags:
N/A
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.53
Change:
-$0.05
(
-10.15%)
Days Range: $0.53 - $0.59
Beta: -
52wk. High: $1.24
52wk. Low: $0.24
Ytd. Change -37.13%
50 Day Moving Average: $0.51
200 Day Moving Average: $0.63
Shares Outstanding: 17989687
Valuation
Market Cap: 953.6M
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A